Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab or Canakinumab in Dry Eye Syndrome
NCT01250171Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Primary completion
- Sep 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab, canakinumab in dry eye syndrome (DED), sponsored by Novartis. Started Nov 2010; status: completed.
02
Drugs
secukinumabcanakinumab
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01250171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01250171.